Publication: UNSUPERVISED CLUSTERING ANALYSIS OF THE SERUM PROTEOME IDENTIFIES SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH DISTINCTIVE DISEASE SEVERITY AND LUPUS NEPHROPATHY
Loading...
Identifiers
Date
2022-06-01
Authors
Lopez-Pedrera, C.
Aguirre-Zamorano, M. A.
Munoz-Barrera, L.
Sanchez-Pareja, I.
Pilar, F. U.
Abalos-Aguilera, M. C.
Puerto, N. Barbarroja
Estevez, E. Collantes
Castro, R. Ortega
Perez-Sanchez, C.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
BMJ Group
Abstract
Background: Systemic lupus erythematosus (SLE) is a remarkably heterogeneous autoimmune disease. Despite great efforts, our knowledge of serum protein
patterns in severe SLE phenotypes is still limited.
Objectives: This study investigated the serum proteomic profile of SLE, in order
to identify relevant clinical patterns.
Methods: Proximity extension immunoassay (PEA, Olink) was used to
assess the serum levels of one hundred and eighty-four inflammation and
organ damage-related proteins in patients with SLE (n = 72) and agematched healthy donors (HD) (n = 18). In parallel, an extensive clinical and
analytical profile of recruited subjects was performed. To evaluate the contribution of molecular profiles to the disease severity, unsupervised clustering analyses were developed.
Description
MeSH Terms
Humans
Blood Proteins
Autoimmune Diseases
Phenotype
Inflammation
Patient Acuity
Blood Proteins
Autoimmune Diseases
Phenotype
Inflammation
Patient Acuity
DeCS Terms
Enfermedades autoinmunes
Fenotipo
Gravedad del paciente
Inflamación
Proteínas sanguíneas
Fenotipo
Gravedad del paciente
Inflamación
Proteínas sanguíneas
CIE Terms
Keywords
Pisum sativum, Proteomics, Lupus Erythematosus, Systemic
Citation
Lopez-Pedrera C, Aguirre-Zamorano MÁ, Muñoz-Barrera L, Sanchez-Pareja I, Pilar FU, Ábalos-Aguilera MC, et al. POS0465 UNSUPERVISED CLUSTERING ANALYSIS OF THE SERUM PROTEOME IDENTIFIES SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH DISTINCTIVE DISEASE SEVERITY AND LUPUS NEPHROPATHY. Annals Of The Rheumatic Diseases [Internet]. 23 de mayo de 2022;81(Suppl 1):486.2-487